Merrimack receives $5 million milestone payment from Shire
Merrimack Pharmaceuticals announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017. September 20, 2018